Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
LPCN
Upturn stock ratingUpturn stock rating

Lipocine Inc (LPCN)

Upturn stock ratingUpturn stock rating
$3.04
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: LPCN (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

2 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $7.38

1 Year Target Price $7.38

Analysts Price Target For last 52 week
$7.38 Target price
52w Low $2.68
Current$3.04
52w High $6.17

Analysis of Past Performance

Type Stock
Historic Profit -1.78%
Avg. Invested days 21
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 16.47M USD
Price to earnings Ratio -
1Y Target Price 7.38
Price to earnings Ratio -
1Y Target Price 7.38
Volume (30-day avg) 2
Beta 1.24
52 Weeks Range 2.68 - 6.17
Updated Date 08/15/2025
52 Weeks Range 2.68 - 6.17
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.84

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date 2025-08-05
When -
Estimate -0.4
Actual -0.41

Profitability

Profit Margin -107.11%
Operating Margin (TTM) -386.03%

Management Effectiveness

Return on Assets (TTM) -16.76%
Return on Equity (TTM) -23.51%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -1461780
Price to Sales(TTM) 3.91
Enterprise Value -1461780
Price to Sales(TTM) 3.91
Enterprise Value to Revenue 0.62
Enterprise Value to EBITDA 0.65
Shares Outstanding 5419050
Shares Floating 5261244
Shares Outstanding 5419050
Shares Floating 5261244
Percent Insiders 2.91
Percent Institutions 9.72

ai summary icon Upturn AI SWOT

Lipocine Inc

stock logo

Company Overview

overview logo History and Background

Lipocine Inc. is a pharmaceutical company focused on developing innovative treatments for men's and women's health conditions utilizing its proprietary oral delivery technology. Founded in 2002, it has evolved from focusing solely on testosterone replacement therapy to exploring broader applications of its technology.

business area logo Core Business Areas

  • Androgen Therapies: Focuses on developing oral testosterone replacement therapies for hypogonadism, including TLANDO.
  • Women's Health: Exploring potential applications of its oral delivery technology in women's health, including pre-term birth prevention.

leadership logo Leadership and Structure

Lipocine's leadership team consists of experienced pharmaceutical executives. Its organizational structure is typical of a small, publicly traded biotechnology company.

Top Products and Market Share

overview logo Key Offerings

  • TLANDO: An oral testosterone replacement therapy approved for hypogonadism. Market share data is not readily available due to its relatively recent launch and evolving competitive landscape. Competitors include injectable testosterone products (e.g., Depo-Testosterone), topical gels (e.g., AndroGel), and other oral therapies (e.g., Jatenzo). Revenue data is tracked in Lipocine's financial reports.

Market Dynamics

industry overview logo Industry Overview

The market for testosterone replacement therapy is mature but still growing, driven by an aging population and increasing awareness of hypogonadism. The women's health market is large and diverse.

Positioning

Lipocine aims to differentiate itself through its oral delivery technology, offering patients a more convenient and potentially safer alternative to existing therapies.

Total Addressable Market (TAM)

The TAM for testosterone replacement therapy is estimated to be in the billions of dollars annually. Lipocine aims to capture a significant share of this market with TLANDO, and expand to other therapies such as pre-term birth prevention

Upturn SWOT Analysis

Strengths

  • Proprietary oral delivery technology
  • Approved product (TLANDO)
  • Experienced management team
  • Potential for pipeline expansion in women's health

Weaknesses

  • Limited financial resources
  • Dependence on a single approved product
  • Commercialization challenges for TLANDO
  • History of regulatory setbacks

Opportunities

  • Expanding TLANDO market share
  • Developing new formulations using its oral delivery technology
  • Partnering with larger pharmaceutical companies
  • Addressing unmet needs in women's health

Threats

  • Competition from established testosterone therapies
  • Regulatory hurdles for new product approvals
  • Patent challenges
  • Market acceptance of oral testosterone

Competitors and Market Share

competitor logo Key Competitors

  • ABBV
  • ENDP
  • AGRX

Competitive Landscape

Lipocine's competitive advantage lies in its oral delivery technology, but it faces competition from established players with greater resources and market presence.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been limited due to regulatory delays and commercialization challenges.

Future Projections: Future growth depends on the success of TLANDO and pipeline development. Analyst estimates vary widely.

Recent Initiatives: Recent initiatives include focusing on TLANDO commercialization and exploring new applications of its oral delivery technology.

Summary

Lipocine is a small pharmaceutical company with an approved product and a proprietary technology. It faces challenges related to commercialization, regulatory hurdles, and limited financial resources. Success depends on expanding the market share for TLANDO and developing its pipeline. The company's volatile stock price reflects the high-risk, high-reward nature of the biotechnology industry.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • SEC Filings (10-K, 10-Q)
  • Lipocine Investor Relations
  • Analyst Reports
  • Market Research Reports

Disclaimers:

This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on individual due diligence and consultation with a qualified financial advisor. Market share data is approximate and may vary.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Lipocine Inc

Exchange NASDAQ
Headquaters Salt Lake City, UT, United States
IPO Launch date 2013-10-22
Co-Founder, Interim Principal Financial Officer, Director, President & CEO Dr. Mahesh V. Patel Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 16
Full time employees 16

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include LPCN 1111 (TLANDO XR), a next-generation long-acting oral product candidate for TRT; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the treatment of cirrhosis; LPCN 1154 to treat postpartum depression; LPCN 2101, a NAS candidate for women with epilepsy; and LPCN 2203, an oral candidate for management of essential tremor. It also develops LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of metabolic dysfunction-associated steatohepatitis; LPCN 2401 to improve body composition in obesity management; and LPCN 1107, an oral hydroxy progesterone caproate product indicated for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.